We are live on ! Find out more
MBRX icon

Moleculin Biotech
MBRX

13 hedge funds and large institutions have $8.57M invested in Moleculin Biotech in 2021 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 2

0.47% less ownership

Funds ownership: 10.47% → 10% (-0.47%)

28% less funds holding

Funds holding: 18 → 13 (-5)

69% less capital inflows, than outflows

Capital inflows: $210K | Capital outflows: $673K

83% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 6

Holders
13
Holders Change
-5
Holders Change %
-27.78%
% of All Funds
0.23%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
2
Reduced
2
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Sio Capital Management
Sio Capital Management
New York
+$117K
2
Charles Schwab
Charles Schwab
California
+$70.1K
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$23.4K

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$140K
2
XTX Topco
XTX Topco
Cayman Islands
-$121K
3
GSA Capital Partners
GSA Capital Partners
United Kingdom
-$114K
4
Goldman Sachs
Goldman Sachs
New York
-$94K
5
Virtu Financial
Virtu Financial
New York
-$93K

MBRX Hedge Fund Activity: Q3 2021 in Review

13 of the 5,731 institutional investors tracked by Wall St. Rank reported a position in Moleculin Biotech (MBRX) for Q3 2021, worth a combined $8.57M — down 22% from $10.9M a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of MBRX and 1 opened new positions — a net loss of 5 holders — while 2 trimmed existing stakes and 2 added.

The largest buyer was Sio Capital Management, adding an estimated $117K. The largest seller was Citadel Advisors, exiting entirely with an estimated $140K sold.

  • 13 institutional investors held Moleculin Biotech (MBRX) as of Q3 2021, down from 18 in Q2 2021.
  • Funds reported $8.57M of Moleculin Biotech stock for Q3 2021, down 22% quarter-over-quarter.
  • 1 fund opened new Moleculin Biotech positions in Q3 2021 and 6 closed out, a net change of -5 holders.
  • The largest Moleculin Biotech buyer in Q3 2021 was Sio Capital Management, an estimated $117K added.
  • The largest Moleculin Biotech seller in Q3 2021 was Citadel Advisors, an estimated $140K sold.

Based on aggregated 13F filings for Q3 2021.